Peritoneal relapse from lung adenocarcinoma after a response to EGFR-TKI

References (8)

1. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-400.
2. Kurishima K, Satoh H, Kaburagi T, Nishimura Y, Shinohara Y, Inagaki M, et al. Erlotinib for elderly patients with non-small cell lung cancer: subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. Mol Clin Oncol 2013; 1: 828-832. Jiménez Mateos A, Cabrera Naranjo F, González Hernández A, Fabre Pi O, Díaz Nicolás S, López Fernández JC. Neoplastic meningitis. Review of a clinical series. Neurologia 2011; 26: 227-32.
3. Satoh H, Ishikawa H, Yamashita YT, Kurishima K, Ohtsuka M, Sekizawa K. Peritoneal carcinomatosis in lung cancer patients. Oncol Rep 2001; 8: 1305-7.
4. Ano S, Satoh H, Nakazawa K, Ohtsuka M, Anami Y, Noguchi M, et al. Malignant meningitis secondary to lung adenocarcinoma: an unusual relapse. Intern Med 2007; 46: 1749-51.
5. Su HT, Tsai CM, Perng RP. Peritoneal carcinomatosis in lung cancer. Respirology 2008; 13: 465-7.
6. Mitsui H, Nakajima J, Maruyama T, Hanajiri K, Omata M. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003; 361: 1993.
7. Kurishima K, Miyazaki K, Tamura T, Ohara G, Kagohashi K, Kawaguchi M, et al. Peritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: a case report. Mol Clin Oncol 2013; 1: 785-7.
8. McNeill PM, Wagman LD, Neifeld JP. Small bowel metastases from primary carcinoma of the lung. Cancer 1987; 59: 1486-9.